{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:59:35Z","timestamp":1793235575395,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10096-025-05106-8","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T12:35:44Z","timestamp":1742301344000},"page":"1349-1355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Investigational antibiotic cefepime\/zidebactam as a therapeutic option for the treatment of an unyielding empyema in a paediatric patient caused by extensively drug-resistant Pseudomonas aeruginosa: a case report"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8853-3308","authenticated-orcid":false,"given":"Vishnu Rao","family":"Polati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Gattu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Nagarjuna","family":"Maturu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Swati","family":"Prakasham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Maqsood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"5106_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1017\/S0950268806006893","volume":"135","author":"AP Zavascki","year":"2007","unstructured":"Zavascki AP, Goldani LZ, Gon\u00e7alves AL et al (2007) High prevalence of metallo-beta-lactamase-mediated resistance challenging antimicrobial therapy against Pseudomonas aeruginosa in a Brazilian teaching hospital. Epidemiol Infect 135:343\u2013345","journal-title":"Epidemiol Infect"},{"key":"5106_CR2","doi-asserted-by":"crossref","unstructured":"Moya B, Barcelo IM, Bhagwat S et al (2017) Potent beta-Lactam enhancer activity of zidebactam and WCK 5153 against acinetobacter baumannii, including Carbapenemase-Producing clinical isolates. Antimicrob Agents Chemother; 61","DOI":"10.1128\/AAC.01238-17"},{"key":"5106_CR3","doi-asserted-by":"crossref","unstructured":"Sader HS, Castanheira M, Huband M et al (2017) WCK 5222 (Cefepime-Zidebactam) antimicrobial activity against clinical isolates of Gram-Negative bacteria collected worldwide in 2015. Antimicrob Agents Chemother; 61","DOI":"10.1128\/AAC.00072-17"},{"key":"5106_CR4","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/jac\/dkaa036","volume":"75","author":"B Moya","year":"2020","unstructured":"Moya B, Bhagwat S, Cabot G et al (2020) Effective Inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa. J Antimicrob Chemother 75:1474\u20131478","journal-title":"J Antimicrob Chemother"},{"key":"5106_CR5","doi-asserted-by":"crossref","unstructured":"Moya B, Barcelo IM, Bhagwat S et al (2017) WCK 5107 (Zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent beta-Lactam enhancer activity against Pseudomonas aeruginosa, including Multidrug-Resistant Metallo-beta-Lactamase-Producing High-Risk clones. Antimicrob Agents Chemother; 61","DOI":"10.1128\/AAC.02529-16"},{"key":"5106_CR6","doi-asserted-by":"publisher","first-page":"e0111823","DOI":"10.1128\/mbio.01118-23","volume":"14","author":"AM Hujer","year":"2023","unstructured":"Hujer AM, Marshall SH, Mack AR et al (2023) Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through beta-lactam-enhancer-mechanism-based cefepime\/zidebactam. mBio 14:e0111823","journal-title":"mBio"},{"key":"5106_CR7","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious diseases society of America 2024 guidance on the treatment of Antimicrobial-Resistant Gram-Negative infections. Clin Infect Dis ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403","DOI":"10.1093\/cid\/ciae403"},{"key":"5106_CR8","unstructured":"https:\/\/em100.edaptivedocs.net\/partner\/clsi\/m100\/CLSIInvestigationalUseOnlyBreakpoints2024.pdf"},{"key":"5106_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1128\/AAC.04238-14","volume":"59","author":"ML Winkler","year":"2015","unstructured":"Winkler ML, Papp-Wallace KM, Hujer AM et al (2015) Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 59:1020\u20131029","journal-title":"Antimicrob Agents Chemother"},{"key":"5106_CR10","doi-asserted-by":"crossref","unstructured":"L\u00f3pez M, Rojo-Bezares B, Chich\u00f3n G et al (2022) Resistance to fluoroquinolones in Pseudomonas aeruginosa from human, animal, food and environmental origin: the role of CrpP and mobilizable ICEs. Antibiot (Basel Switzerland); 11","DOI":"10.3390\/antibiotics11091271"},{"key":"5106_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2217\/fmb.14.135","volume":"10","author":"SS Jean","year":"2015","unstructured":"Jean SS, Lee WS, Lam C et al (2015) Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. Future Microbiol 10:407\u2013425","journal-title":"Future Microbiol"},{"key":"5106_CR12","doi-asserted-by":"crossref","unstructured":"Bissantz C, Zampaloni C, David-Pierson P et al (2024) Translational PK\/PD for the Development of Novel Antibiotics-A Drug Developer\u2019s Perspective. Antibiot (Basel Switzerland); 13","DOI":"10.3390\/antibiotics13010072"},{"key":"5106_CR13","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/jac\/dkad114","volume":"78","author":"JN Moore","year":"2023","unstructured":"Moore JN, Poon L, Pahwa S et al (2023) Animal pharmacokinetics\/pharmacodynamics (PK\/PD) infection models for clinical development of antibacterial drugs: lessons from selected cases. J Antimicrob Chemother 78:1337\u20131343","journal-title":"J Antimicrob Chemother"},{"key":"5106_CR14","first-page":"149","volume":"75","author":"JM Kidd","year":"2020","unstructured":"Kidd JM, Abdelraouf K, Nicolau DP (2020) Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model. J Antimicrob Chemother 75:149\u2013155","journal-title":"J Antimicrob Chemother"},{"key":"5106_CR15","doi-asserted-by":"crossref","unstructured":"Monogue ML, Tabor-Rennie J, Abdelraouf K et al (2019) In vivo efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the neutropenic murine thigh infection model. Antimicrob Agents Chemother; 63","DOI":"10.1128\/AAC.00233-19"},{"key":"5106_CR16","unstructured":"Huband MD, Castanheira M, Jones RN, Rhomberg PR, Watters AA, Sader HS WCK 5222 (Cefepime-Zidebactam) In Vitro Time-kill Studies against Pseudomonas aeruginosa and Acinetobacter baumannii Isolates with Characterized \u03b2-lactamases. ASM MICROBE 2016, Friday-477, Boston, MA, June 16\u201320"},{"key":"5106_CR17","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1093\/jac\/dkab213","volume":"76","author":"I Barcelo","year":"2021","unstructured":"Barcelo I, Cabot G, Palwe S et al (2021) In vitro evolution of cefepime\/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy. J Antimicrob Chemother 76:2546\u20132557","journal-title":"J Antimicrob Chemother"},{"key":"5106_CR18","doi-asserted-by":"publisher","first-page":"e0172422","DOI":"10.1128\/spectrum.01724-22","volume":"10","author":"JA Karlowsky","year":"2022","unstructured":"Karlowsky JA, Walkty AJ, Baxter MR et al (2022) In vitro activity of Cefiderocol against extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019. Microbiol Spectr 10:e0172422","journal-title":"Microbiol Spectr"},{"key":"5106_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1089\/mdr.2023.0090","volume":"29","author":"L Malisova","year":"2023","unstructured":"Malisova L, Vrbova I, Pomorska K et al (2023) In vitro activity of Cefiderocol against Carbapenem-Resistant enterobacterales and Pseudomonas aeruginosa. Microb Drug Resist (Larchmont NY) 29:485\u2013491","journal-title":"Microb Drug Resist (Larchmont NY)"},{"key":"5106_CR20","doi-asserted-by":"publisher","first-page":"e0160022","DOI":"10.1128\/jcm.01600-22","volume":"61","author":"PJ Simner","year":"2023","unstructured":"Simner PJ, Palavecino EL, Satlin MJ et al (2023) Potential of inaccurate Cefiderocol susceptibility results: a CLSI AST subcommittee advisory. J Clin Microbiol 61:e0160022","journal-title":"J Clin Microbiol"},{"key":"5106_CR21","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1093\/jac\/dkab280","volume":"76","author":"T Katsube","year":"2021","unstructured":"Katsube T, Nicolau DP, Rodvold KA et al (2021) Intrapulmonary Pharmacokinetic profile of Cefiderocol in mechanically ventilated patients with pneumonia. J Antimicrob Chemother 76:2902\u20132905","journal-title":"J Antimicrob Chemother"},{"key":"5106_CR22","doi-asserted-by":"crossref","unstructured":"Mushtaq S, Sadouki Z, Vickers A et al (2020) In vitro activity of cefiderocol, a siderophore cephalosporin, against Multidrug-Resistant Gram-Negative bacteria. Antimicrob Agents Chemother; 64","DOI":"10.1128\/AAC.01582-20"},{"key":"5106_CR23","doi-asserted-by":"crossref","unstructured":"Karakonstantis S, Rousaki M, Kritsotakis EI, Cefiderocol (2022) Systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiot (Basel Switzerland); 11","DOI":"10.3390\/antibiotics11060723"},{"key":"5106_CR24","doi-asserted-by":"crossref","unstructured":"Soman R, Sirsat R, Sunavala A et al (2024) Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by new Delhi metallo-beta-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime\/zidebactam (WCK 5222). Eur J Clin Microbiol Infect Dis","DOI":"10.1007\/s10096-024-04791-1"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05106-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05106-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05106-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:57:15Z","timestamp":1748350635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05106-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["5106"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05106-8","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cefepime\/zidebactam treatment was initiated on compassionate grounds with due approval from CDSCO (Indian Drug Regulator) and also from hospital ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}